Unsurprisingly, deletion of CD8+ T cells led to the fastest tumor growth and almost abolished the therapeutic effect of macrophage-specific Ubc9 deficiency (Figure 7, A–C), which further supported the notion that the antitumor effect of TAMs is predominantly due to the priming of CD8+ T cells. This evidence concerns the gene UBE2I and neoplasm.